TICKERNERD
Menu
XGNXGNHealthcare · Diagnostics & Research

XGN Stock Forecast: Exagen, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$8.41
+6.86% on the day

The 7 Wall Street analysts covering Exagen, Inc. hold a median 12-month price target of $10 — +18.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$203.7M
Ticker Nerd rank
64 / 100
Median analyst target
$10
Analysts covering
7
Revenue$19.9M+15.9% y/y
Operating income−$1.7M
Net income−$3.2M
Free cash flow$3.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+19.6%
1M
+27.6%
YTD
+38.3%
1Y
−12.8%
From 52W high
−29.7%
From 52W low
+217.4%
$3
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Exagen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Revisions
76
Growth
73
Size
68
Quality
59
Value
50
Momentum
42
Volatility
21
Issuance
16

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26XGNHigh $12Median $10Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $9Median $10High $12

The green dot is the last close — the median target sits +18.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
5 Aug 2026B. Riley SecuritiesReiteratesBuy$8.00 → $12
5 Aug 2026BTIGMaintainsBuy$8.00 → $9.00
5 Aug 2026TD CowenMaintainsBuy$8.00 → $10
25 June 2026Roth CapitalInitiatesBuy$8.00
25 June 2026Roth CapitalInitiatesBuy—
12 May 2026BTIGMaintainsBuy—
20 Apr 2026Canaccord GenuityMaintainsBuy—
11 Mar 2026Canaccord GenuityMaintainsBuy—
11 Mar 2026Craig-HallumMaintainsBuy—
11 Mar 2026KeybancMaintainsOverweight—
10 Mar 2026BTIGMaintainsBuy—
24 Feb 2026TD CowenMaintainsBuy—
17 Feb 2026BTIGMaintainsBuy—
30 Jan 2026B. Riley SecuritiesReiteratesBuy—
10 Nov 2025BTIGMaintainsBuy—
5 Nov 2025B. Riley SecuritiesReiteratesBuy—
27 Oct 2025Canaccord GenuityMaintainsBuy—
22 Oct 2025BTIGMaintainsBuy—
14 Oct 2025KeybancMaintainsOverweight—
11 Sept 2025B. Riley SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Exagen, Inc. returned −12.8% against +16.3% for the S&P 500, dividends included.

XGN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26XGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Exagen, Inc. (XGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.0×

Cheaper than 92% of US stocks

Price / sales
2.9×

Cheaper than 42% of US stocks

Price / book
16.7×

Cheaper than 6% of US stocks

EV / EBITDA
−19.2×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
15.9%

Higher than 64% of US stocks

Earnings growth (YoY)
15.9%

Higher than 54% of US stocks

Gross margin
61.3%

Higher than 74% of US stocks

Operating margin
−8.6%

Higher than 25% of US stocks

Net margin
−26.6%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−113.8%

Higher than 12% of US stocks

Return on assets
−14.9%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Exagen, Inc. (XGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Exagen, Inc. has a market value of $203.7M and an enterprise value of $206.8M.

  • Revenue in the twelve months to 30 June 2026: $71.1M. The latest quarter grew 15.9% year on year.

  • Net income over the same four quarters: −$18.9M, a −26.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.81.

  • Free cash flow in the twelve months to 30 June 2026: −$7.6M.

  • Shares outstanding: 24.2M.

  • Trailing P/E: −9.0×; forward P/E: −17.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Exagen, Inc. employs 216 people — $329K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

XGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
XGNExagen, Inc.$203.7M
64
BDSXBiodesix, Inc.$302.4M
86
IMDXInsight Molecular Diagnostics, Inc.$128.7M
40
QUCYQuantum Cyber NV$116.0M
6
MYGNMyriad Genetics, Inc.$363.7M
45
FLGTFulgent Genetics, Inc.$616.0M
41
PRPOPrecipio, Inc.$46.4M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Exagen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XGN news & analysis

Exagen Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026positive

Exagen reported record second-quarter revenue during its Q2 earnings call, driven by growth in AVISE CTD test volume, average selling price, and Pharma Services revenue. The company came close to achieving adjusted EBITDA break-even.

Why it matters — A stock watcher would care because record revenue across key growth drivers brings the company close to adjusted EBITDA break-even, a notable milestone for its profitability trajectory.

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Exagen Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.

Why it matters — Earnings-call transcripts provide shareholders and analysts with direct insight into management's commentary on the quarter's results and outlook.

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 4 Aug 2026positive

Exagen Inc. (XGN) reported a second-quarter loss of $0.13 per share, narrower than the Zacks Consensus Estimate of a $0.19 loss and improved from the $0.18 loss a year ago. The report beat revenue estimates.

Why it matters — The quarter exceeded analyst expectations on earnings and revenue, with a narrower year-over-year loss, making the results noteworthy for Exagen watchers.

Exagen Inc. Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 4 Aug 2026positive

Exagen Inc. reported second-quarter 2026 financial results, achieving record total revenue, test volume, and trailing twelve-month average selling price, while reducing net loss by nearly 30% and narrowing adjusted EBITDA loss to $0.1 million. The company also increased its full-year revenue guidance to between $72 million and $75 million.

Why it matters — XGN watchers would note the record revenue and test volume, sharp reduction in losses, and raised full-year guidance as indicators of improving operational and financial performance.

Exagen Inc. to Participate in Upcoming Investor Conference

GlobeNewsWire · 28 July 2026neutral

Exagen Inc. announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, with a Fireside Chat that will be webcast on the company's investor relations website.

Why it matters — The conference participation gives Exagen a platform to present its autoimmune testing business to investors and analysts.

FAQ

Frequently asked questions about XGN stock

What is the XGN stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Exagen, Inc. have a median 12-month price target of $10, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XGN stock a buy right now?

Of the 7 analysts covering Exagen, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Exagen, Inc. 64 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XGN?

As at 19 Sept 2026, Exagen, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

Will XGN stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +18.9% from the last close, and Ticker Nerd's factor model ranks Exagen, Inc. 64 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XGN stock forecast for 2030?

No analyst covering Exagen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.

How has XGN stock performed over the past year?

Exagen, Inc. returned -12.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Exagen, Inc. do?

Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing.

What is the latest news on XGN?

The most recent item we track (MarketBeat, 4 Aug 2026): "Exagen Q2 Earnings Call Highlights". Exagen reported record second-quarter revenue during its Q2 earnings call, driven by growth in AVISE CTD test volume, average selling price, and Pharma Services revenue. The company came close to achieving adjusted EBITDA break-even.

Company

About Exagen, Inc.

Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing. It develops and commercializes blood-based laboratory tests under its AVISE brand, supporting clinicians in the diagnosis, prognosis, and monitoring of complex rheumatic and autoimmune conditions. Its portfolio is centered on helping healthcare providers assess diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease with greater clinical clarity. Exagen’s products are used primarily in rheumatology and autoimmune care, where accurate differentiation among overlapping conditions is especially important. The company combines proprietary biomarkers, serology, and cell-based assay technologies to deliver specialized testing solutions for physicians, laboratories, and other healthcare partners. Exagen Inc. plays a focused role in the medical diagnostics market by addressing the needs of patients with chronic autoimmune disorders through specialized laboratory services and branded diagnostic products.

CEO Mr. John Aballi · 216 employees · United States · https://www.exagen.com